Microbot Medical Inc. (NasdaqCM: MBOT) will look for acquisitions. Microbot Medical Inc. announced $5.9 million registered direct offering priced at-the-market. The gross proceeds to Microbot, before deducting placement agent fees and other offering expenses, are expected to be approximately $5.9 million. Microbot currently intends to use the net proceeds from the offering for the continuous development of its SCS device for the treatment of hydrocephalus and NPH, to expand and develop additional applications deriving from its existing IP portfolio, including the potential addition of complementary assets to the CardioSert portfolio either through internal development, in-license or acquisition, and for working capital and other general corporate purposes.